Talis Biomedical Price to Free Cash Flow Ratio 2020-2024 | TLIS

Talis Biomedical price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as

Talis Biomedical Price to Free Cash Flow Ratio 2020-2024 | TLIS

Talis Biomedical price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$145.5B
Vertex Pharmaceuticals (VRTX)$119.4B
Gilead Sciences (GILD)$114.5B
Bristol Myers Squibb (BMY)$113.1B
CSL (CSLLY)$84.9B
Regeneron Pharmaceuticals (REGN)$80.4B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.7B
Alnylam Pharmaceuticals (ALNY)$31.7B
BioNTech SE (BNTX)$28.6B
Illumina (ILMN)$22.8B
Biogen (BIIB)$21.9B
BeiGene (BGNE)$17.5B
Moderna (MRNA)$16.1B
Genmab (GMAB)$13.3B
Incyte (INCY)$13.2B
Insmed (INSM)$12.8B
BioMarin Pharmaceutical (BMRN)$12.6B
Bio-Techne Corp (TECH)$12B
Sarepta Therapeutics (SRPT)$11.8B
Exact Sciences (EXAS)$11.3B
Vaxcyte (PCVX)$10.9B
QIAGEN (QGEN)$10.4B
Exelixis (EXEL)$10B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$8.8B
Repligen (RGEN)$8.8B
Roivant Sciences (ROIV)$8.6B
Ascendis Pharma (ASND)$7.9B
Revolution Medicines (RVMD)$7.6B